{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:11:34Z","timestamp":1790111494854,"version":"4.0.1"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"kind of funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Increasing numbers of BReast CAncer (BRCA) 1 or 2 pathogenic variant (PV) carriers, who have an inherited predisposition to breast and ovarian cancer, are being identified. Among these women, data regarding the effects of contraception on cancer risks are unclear and various guidelines provide various recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVE AND RATIONALE<\/jats:title>\n                  <jats:p>We aim to optimize counselling regarding contraception for BRCA1\/2-PV carriers. Therefore, we performed a systematic review and meta-analysis. We investigated the risk ratio for developing breast cancer or ovarian cancer in BRCA1\/2-PV carriers who have used any form of contraception versus non-users. Second, we analysed breast and ovarian cancer risk among BRCA1\/2-PV carriers as influenced by the duration of contraceptive use and by the time since last use. In addition, we provide an overview of all relevant international guidelines regarding contraceptive use for BRCA1\/2-PV carriers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SEARCH METHODS<\/jats:title>\n                  <jats:p>A systematic search in the Medline database and Cochrane library identified studies describing breast and\/or ovarian cancer risk in BRCA1\/2-PV carriers as modified by contraception until June 2021. The search included medical subject headings, keywords and synonyms related to BRCA and contraceptives (any kind). PRISMA guidance was followed. Risk Of Bias In Non-randomized Studies of Interventions and Grading of Recommendations, Assessment, Development and Evaluations assessments were performed. Random-effects meta-analyses were used to estimate pooled effects for breast and ovarian cancer risk separately. Subgroup analyses were conducted for BRCA1 versus BRCA2 and for the various contraceptive methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OUTCOMES<\/jats:title>\n                  <jats:p>Results of the breast cancer risk with oral contraceptive pill (OCP) analysis depended on the outcome measure. Meta-analyses of seven studies with 7525 women revealed a hazard ratio (HR) of 1.55 (95% CI: 1.36\u20131.76) and of four studies including 9106 women resulted in an odds ratio (OR) of 1.06 (95% CI: 0.90\u20131.25), heterogeneity (I2) 0% and 52%, respectively. Breast cancer risk was still increased in ever-users compared with never-users &amp;gt;10\u2009years after last OCP use. In contrast, ovarian cancer risk was decreased among OCP users: HR 0.62 (95% CI: 0.52\u20130.74) based on two studies including 10\u00a0981 women (I2: 0%), and OR 0.49 (95% CI: 0.38\u20130.63) based on eight studies including 10\u00a0390 women (I2: 64%). The protective effect vanished after cessation of use. Tubal ligation also protects against ovarian cancer: one study including 3319 women (I2: 0%): HR: 0.44 (95% CI: 0.26\u20130.74) and three studies with 7691 women (I2: 44%): OR: 0.74 (95% CI: 0.53\u20131.03). Data regarding other contraceptives were unavailable. No differences were observed between BRCA1 and BRCA2-PV carriers. The quality of evidence was either low or very low.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS<\/jats:title>\n                  <jats:p>The OCP potentially increases breast cancer risk, while ovarian cancer risk decreases with either the OCP and tubal ligation in BRCA1\/2-PV carriers. Counselling of BRCA1\/2-PV carriers should be personalized; the genetic and non-genetic factors (like prior risk-reducing surgeries, prior breast cancer and age) and patients\u2019 preferences (reversibility, ease of use, reliability and effect on menstrual cycle) should be balanced. To further optimize counselling for high-risk women, future research should focus on other (commonly used) contraceptive methods and cancer risks in this specific population, and on the potential impact of changing formulations over time.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humupd\/dmac038","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T15:47:04Z","timestamp":1668613624000},"page":"197-217","source":"Crossref","is-referenced-by-count":35,"title":["Contraceptives and cancer risks in <i>BRCA1\/2<\/i> pathogenic variant carriers: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7562-9861","authenticated-orcid":false,"given":"Majke H D","family":"van Bommel","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Radboud University Medical Center, Radboud Institute for Health Sciences , Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"IntHout","sequence":"additional","affiliation":[{"name":"Department for Health Evidence, Radboud University Medical Center, Radboud Institute for Health Sciences , Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guus","family":"Veldmate","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Gelderse Vallei Hospital , Ede, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Marleen","family":"Kets","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Radboud University Medical Center , Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne A","family":"de Hullu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Radboud University Medical Center, Radboud Institute for Health Sciences , Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"van Altena","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Radboud University Medical Center, Radboud Institute for Health Sciences , Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marline G","family":"Harmsen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Radboud University Medical Center, Radboud Institute for Health Sciences , Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"2023051109501975700_dmac038-B1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1\/2 Carrier Cohort Study","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023051109501975700_dmac038-B2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/01443615.2020.1789960","article-title":"Ever-use of the intra-uterine device and the risk of ovarian cancer","volume":"41","author":"Balayla","year":"2021","journal-title":"J Obstet Gynaecol"},{"key":"2023051109501975700_dmac038-B3","author":"Barnhoorn","year":"2020"},{"key":"2023051109501975700_dmac038-B4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"2023051109501975700_dmac038-B5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10549-011-1509-z","article-title":"Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation","volume":"129","author":"Bernholtz","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2023051109501975700_dmac038-B6","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group","volume":"25","author":"Brohet","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023051109501975700_dmac038-B7","author":"Central Bureau for Statistics","year":"2013"},{"key":"2023051109501975700_dmac038-B8","doi-asserted-by":"crossref","first-page":"pkaa029","DOI":"10.1093\/jncics\/pkaa029","article-title":"Penetrance of breast and ovarian cancer in women who carry a BRCA1\/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis","volume":"4","author":"Chen","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2023051109501975700_dmac038-B9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humupd\/dmq022","article-title":"Hormonal contraception and risk of cancer","volume":"16","author":"Cibula","year":"2010","journal-title":"Hum Reprod Update"},{"key":"2023051109501975700_dmac038-B10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/humupd\/dmq030","article-title":"Tubal ligation and the risk of ovarian cancer: review and meta-analysis","volume":"17","author":"Cibula","year":"2011","journal-title":"Hum Reprod Update"},{"key":"2023051109501975700_dmac038-B11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"2023051109501975700_dmac038-B12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/aogs.13817","article-title":"Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis","volume":"99","author":"Conz","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2023051109501975700_dmac038-B13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/1047-2797(94)00098-E","article-title":"Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer","volume":"5","author":"Cramer","year":"1995","journal-title":"Ann Epidemiol"},{"key":"2023051109501975700_dmac038-B14","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/humrep\/der274","article-title":"The post-reproductive fallopian tube: better removed?","volume":"26","author":"Dietl","year":"2011","journal-title":"Hum Reprod"},{"key":"2023051109501975700_dmac038-B15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1053\/crad.2002.0940","article-title":"Hormone replacement therapy and mammographic screening","volume":"57","author":"Evans","year":"2002","journal-title":"Clin Radiol"},{"key":"2023051109501975700_dmac038-B16","doi-asserted-by":"crossref","first-page":"dju410","DOI":"10.1093\/jnci\/dju410","article-title":"Ovarian cancer risk after salpingectomy: a nationwide population-based study","volume":"107","author":"Falconer","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2023051109501975700_dmac038-B17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation \u2013 a factor in ovarian neoplasia?","volume":"2","author":"Fathalla","year":"1971","journal-title":"Lancet"},{"key":"2023051109501975700_dmac038-B18","first-page":"292","article-title":"Incessant ovulation and ovarian cancer \u2013 a hypothesis re-visited","volume":"5","author":"Fathalla","year":"2013","journal-title":"Facts Views Vis Obgyn"},{"key":"2023051109501975700_dmac038-B19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/bjc.2013.803","article-title":"Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry","volume":"110","author":"Ferris","year":"2014","journal-title":"Br J Cancer"},{"key":"2023051109501975700_dmac038-B20","doi-asserted-by":"crossref","first-page":"dju091","DOI":"10.1093\/jnci\/dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis","volume":"106","author":"Friebel","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2023051109501975700_dmac038-B21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-005-9051-5","article-title":"Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland","volume":"95","author":"Gronwald","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"2023051109501975700_dmac038-B22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2023051109501975700_dmac038-B23","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1055-9965.EPI-06-0258","article-title":"BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50","volume":"15","author":"Haile","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023051109501975700_dmac038-B24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2016.07.104","article-title":"Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers: a single-center experience","volume":"143","author":"Harmsen","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2023051109501975700_dmac038-B25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2023051109501975700_dmac038-B26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","volume":"177","author":"Heemskerk-Gerritsen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2023051109501975700_dmac038-B27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0361-090X(02)00004-1","article-title":"Oral contraceptives and risk of familial breast cancer","volume":"26","author":"Heimdal","year":"2002","journal-title":"Cancer Detect Prev"},{"key":"2023051109501975700_dmac038-B28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2023051109501975700_dmac038-B29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00404-020-05458-w","article-title":"Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review","volume":"301","author":"Huber","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"2023051109501975700_dmac038-B30","author":"IntegraalKankercentrumNederland","year":"2017"},{"key":"2023051109501975700_dmac038-B31"},{"key":"2023051109501975700_dmac038-B32","doi-asserted-by":"crossref","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"2023051109501975700_dmac038-B33","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer"},{"key":"2023051109501975700_dmac038-B34","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.29386","article-title":"Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","volume":"137","author":"Kotsopoulos","year":"2015","journal-title":"Int J Cancer"},{"key":"2023051109501975700_dmac038-B35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-013-2823-4","article-title":"Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers","volume":"143","author":"Kotsopoulos","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2023051109501975700_dmac038-B36","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2023051109501975700_dmac038-B37","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"key":"2023051109501975700_dmac038-B38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1067\/mob.2002.121896","article-title":"Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density","volume":"186","author":"Lundstr\u00f6m","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"2023051109501975700_dmac038-B39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/aogs.12516","article-title":"Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study","volume":"94","author":"Madsen","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2023051109501975700_dmac038-B40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"key":"2023051109501975700_dmac038-B41","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2023051109501975700_dmac038-B42","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023051109501975700_dmac038-B43","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N Engl J Med"},{"key":"2023051109501975700_dmac038-B44","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","article-title":"Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"94","author":"Narod","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2023051109501975700_dmac038-B45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","article-title":"Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group","volume":"339","author":"Narod","year":"1998","journal-title":"N Engl J Med"},{"key":"2023051109501975700_dmac038-B46","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(00)04642-0","article-title":"Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study","volume":"357","author":"Narod","year":"2001","journal-title":"Lancet"},{"key":"2023051109501975700_dmac038-B47","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.bjc.6603015","article-title":"Surveillance of women at high risk for hereditary ovarian cancer is inefficient","volume":"94","author":"Oei","year":"2006","journal-title":"Br J Cancer"},{"key":"2023051109501975700_dmac038-B48","doi-asserted-by":"crossref","first-page":"102110","DOI":"10.18632\/oncotarget.22193","article-title":"Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"2023051109501975700_dmac038-B49","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.fertnstert.2015.02.011","article-title":"Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers","volume":"103","author":"Perri","year":"2015","journal-title":"Fertil Steril"},{"key":"2023051109501975700_dmac038-B50","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1158\/1055-9965.EPI-20-1355","article-title":"Depot-medroxyprogesterone acetate use is associated with decreased risk of ovarian cancer: the mounting evidence of a protective role of progestins","volume":"30","author":"Phung","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023051109501975700_dmac038-B51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"key":"2023051109501975700_dmac038-B52","author":"R","year":"2021"},{"key":"2023051109501975700_dmac038-B53","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"2023051109501975700_dmac038-B54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1757-2215-5-13","article-title":"Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis","volume":"5","author":"Rice","year":"2012","journal-title":"J Ovarian Res"},{"key":"2023051109501975700_dmac038-B55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mgg3.191","article-title":"Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers","volume":"4","author":"Rieder","year":"2016","journal-title":"Mol Genet Genomic Med"},{"key":"2023051109501975700_dmac038-B56","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2265.1998.00577.x","article-title":"Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence","volume":"49","author":"Riman","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023051109501975700_dmac038-B57","doi-asserted-by":"crossref","first-page":"51.e51\u201351","DOI":"10.1016\/j.ajog.2021.01.014","article-title":"Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study","volume":"225","author":"Schrijver","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2023051109501975700_dmac038-B58","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jnci\/djac004","article-title":"Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits","author":"Schrijver","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2023051109501975700_dmac038-B59","doi-asserted-by":"crossref","first-page":"pky023","DOI":"10.1093\/jncics\/pky023","article-title":"Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study","volume":"2","author":"Schrijver","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"2023051109501975700_dmac038-B60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2023051109501975700_dmac038-B61","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2023051109501975700_dmac038-B62","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.18632\/oncotarget.13423","article-title":"The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation","volume":"8","author":"Toss","year":"2017","journal-title":"Oncotarget"},{"key":"2023051109501975700_dmac038-B63","author":"UnitedNations","year":"2020"},{"key":"2023051109501975700_dmac038-B64","doi-asserted-by":"crossref","first-page":"e1001182","DOI":"10.1371\/journal.pmed.1001182","article-title":"Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study","volume":"9","author":"Urban","year":"2012","journal-title":"PLoS Med"},{"key":"2023051109501975700_dmac038-B65","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/GME.0000000000001844","article-title":"The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer","volume":"28","author":"van Barele","year":"2021","journal-title":"Menopause"},{"key":"2023051109501975700_dmac038-B66","first-page":"211","article-title":"Ovarian cancer risk after salpingectomy for ectopic pregnancy or hydrosalpinx: results of the OCASE nationwide population-based database study","volume":"36","author":"van Lieshout","year":"2021","journal-title":"Hum Reprod"},{"key":"2023051109501975700_dmac038-B67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2010.03.009","article-title":"Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2023051109501975700_dmac038-B68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ygyno.2010.05.012","article-title":"Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers","volume":"118","author":"Vicus","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2023051109501975700_dmac038-B69","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnci\/djz080","article-title":"Universal tumor DNA BRCA1\/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition","volume":"112","author":"Vos","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2023051109501975700_dmac038-B70","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/AOG.0000000000003463","article-title":"Intrauterine device use and ovarian cancer risk: a systematic review and meta-analysis","volume":"134","author":"Wheeler","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2023051109501975700_dmac038-B71","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/sj.bjc.6602239","article-title":"Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations","volume":"91","author":"Whittemore","year":"2004","journal-title":"Br J Cancer"},{"key":"2023051109501975700_dmac038-B72","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1471-0528.2012.03298.x","article-title":"Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study","volume":"119","author":"Wilailak","year":"2012","journal-title":"BJOG"},{"key":"2023051109501975700_dmac038-B73","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2022.01.014","article-title":"Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation","volume":"164","author":"Xia","year":"2022","journal-title":"Gynecol Oncol"}],"container-title":["Human Reproduction Update"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humupd\/article-pdf\/29\/2\/197\/50276268\/dmac038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humupd\/article-pdf\/29\/2\/197\/50276268\/dmac038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:51:35Z","timestamp":1683798695000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humupd\/article\/29\/2\/197\/6831124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,16]]},"published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humupd\/dmac038","relation":{},"ISSN":["1355-4786","1460-2369"],"issn-type":[{"value":"1355-4786","type":"print"},{"value":"1460-2369","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,11,16]]}}}